Summary
Adenoviral vectors, which have targeting ligands for tumor cells on the capsid, no natural tropism, and carry a therapeutic payload should be constructed soon and tested in pre-clinical models. Nevertheless, there are still important considerations for the design and therapeutic use of targetable vectors. Perhaps the single greatest challenge in the future, as it was in the past, will be finding ligands that have a higher apparent affinity for tumor and/or tumor endothelial cells then normal cells. However, the advent of many rapidly advancing technologies and information including the sequencing of the human genome, in vivo and in vitro phage display, rapid analysis of gene and protein expression in any context, and new cellular targets such as angiogenic endothelial cells, may provide many opportunities for the discovery of novel and useful ligands. In addition, the inter-ests in targeting vectors are rapidly growing with new journals and meetings solely devoted to this subject increasing annually. Within the next 5 years, we should have mean-ingful clinical data on targetable vectors to reassess our progress.
Genetic Therapy Inc., A Novartis Company
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Anderson, S.C., Johnson, D.E., Harris, M.P., Engler, H., Hancock, W., Huang, W.M., Wills, K.N., Gregory, R.J., Sutjipto, S., Wen, S.F., Lofgren, S., Shepard, H.M., and Maneval, D.C., 1998. P53 gene therapy in a rat model of hepatocellular carcinoma:intra-arterial delivery of a recombinant adenovirus. Clin. Cancer. Res.7:1649–1659.
Bergelson, J.M., Cunningham, J.A., Droguett, G., Kurt-Jones, E.A., Krithivas, A., Hong, J.S., Horwitz, M.S., Crowell, R.L., and Finberg, R.W. 1997. Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science275:1320–1323.
Bischoff J.R., Kirn D.H., Williams A., Heise C., Horn S., Muna M, Ng L., Nye J.A., Sampson-Johannes A., Fattaey A., and McCormick F, 1996. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science. 274:373–376.
Clary, B.M., and Lyerly, H.K., 1998. Transcriptional targeting for cancer gene therapy. Surg. Oncol. Clin. N. Am.7:565–574.
Connelly, S., Andrews, J.L., Gallo, A.M., Kayda, D.B., Qian, J., Hoyer, L., Kadan, M.J., Gorziglia, M.I., Trapnell, B.C., McClelland, A., and Kaleko, M., 1998. Sustained phenotypic correction of murine hemophilia A by in vivo gene therapy. Blood.91:3273–3281.
Cusack, Jr., J.C., and Tanabe, K.K., 1998. Cancer gene therapy. Surg. Oncol. Clin. N. Am.7:421–469.
Deshane, J., Siegal, G.P., Wang, M., Wright, M., Bucy, R.P., Alvarez, R.D., and Curiel, D.T., 1997. Transductional efficiency and safety of an intraperitoneally delivered adenovirus encoding an anti-erbB-2 intra-cellular single-chain antibody for ovarian cancer gene therapy. Gynecol. Oncol.64:378–385.
Douglas J.T., Rogers B.E., Rosenfeld M.E., Michael S.I., Feng M., and Curiel D.T. 1996. Targeted gene delivery by tropism-modified adenoviral vectors. Nat. Biotechnol.14:1574–1578.
Feng, M., Jackson, W.H., Goldman, C.K., Rancourt, C., Wang, M., Dusing, S.K., Siegal, G., and Curiel, D.T., 1997. Stable in vivo gene transduction via a novel adenoviral/retroviral chimeric vector. Nat. Biotechnol.15:866–870.
Folkman, J., 1996. Fighting cancer by attacking its blood supply. Sci. Am.275:150–154.
Folkman, J., 1998. Antiangiogenic gene therapy. Proc. Natl. Acad Sci. U.S.A., 95:9064–9066.
Goldman C.K., Rogers B.E., Douglas J.T., Sosnowski B.A., Werbin Y. Siegal G.P., Baird A., Campain J.A., and Curiel D., 1997. Targeted gene delivery to Kaposi’s sarcoma cells via the fibroblast growth receptor. Cancer Research57:1447–1451.
Hall F.L., Gordon E.M., Wu L., Zhu N.L., Skotzko M.J., Starnes V.A., and Anderson W.F., 1997. Targeting retroviral vectors to vascular lesions by genetic engineering of the MoMLV gp70 envelope protein. Hum. Gene. Ther.8:2183–2192.
Hallenbeck, P.L., Chang, Y-N., Hay, C., Golightly, D., Stewart, D., McGarrity, G., and Chiang, Y., 1996. Novel tumor specific replication competent adenoviral vector for gene therapy of cancer. Abstracts of the fifth International Conference on gene Therapy of Cancer., November, 1998.
Han, X., Kasahara N., and Kan, Y.W., 1995. Ligand-directed retroviral targeting of human breast cancer cells. Proc. Natl. Acac. Sci. USA.92:9747–9751.
Hong J.S., and Engler J.A., 1996. Domains required for assembly of adenovirus type 2 fiber trimers. J. Virology70:7071–7078.
Kaneko S., Hallenbeck P., Kotani T., Nakabayashi H., McGarrity G., Tamaoki T., Anderson W.F., and Chiang Y.L., 1995. Adenovirus-mediated gene therapy of heptacellular carcinoma using cancer-specific gene expression. Cancer Res.55:5283–5287.
Kasahara, N., Dozy, A.M., and Kan, Y.W., 1994. Tissue specific targeting of retroviral vectors through ligand-receptor interactions. Science266:1373–1376.
Krasnykh, V.N., Mikheeva, G.V., Douglas, J.T., and Curiel, D.T., 1996. Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. J. Virology70:6839–6846.
Krasnykh, V.N., Dmitriev, I., Mikheeva, G., Miller, C.R., Belousova. N., and Curiel, D.T., 1998. Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob. J. Virology72:1844–1852.
Krasnykh, V.N., Douglas, J.T., and Curiel, D.T., 1998. Tropism-modified adenoviral vectors for cell-specific gene delivery. Abstracts of Cold Spring harbor Symposium “Gene Therapy”, September, 1998.
Jain, R.K., 1997. The Eugene M. Landis award lecture 1996. Delivery of molecular and cellular medicine to solid tumors. Microcirculation4:1–23.
Michael, S.I., Hong, J.S., Curiel, D.T., and Engler, J.A., 1995. Addition of a short peptide ligand to the adenovirus fiber protein. Gene Therapy2:660–668.
Molnar-Kimber K.L., Sterman D.H., Chang M., Kang E.H., Elbash M., Lanuti M., Elshami A., Gelfand K., Wilson J.M., Kaiser L.R., and Albelda S.M., 1998. Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma. Human Gene Therapy9:2121–2133.
Niculescu-Duvaz, I., and Springer, C.J., 1996. Development of prodrugs for antibody-directed enzyme prodrug therapy (ADEPT). Exp. Opin. Invest. Drugs.5:289–308.
Novelli A., and Boulanger P.A., 1991. Deletion analysis of functional domains in baculovirus-expressed adenovirus type 2 fiber. Virology185:365–376.
O’Reilly, M.S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R.A., Moses, M., Lane, W.S., Cao, Y., Sage, E.H., and Folkman, J., 1994. Angiostatin:a novel angiogenesis inhibitor that mediates the supression of metas-tases by a Lewis lung carcinoma. Cell.79:315–328.
Rabin, D., Buchsbaum, D.J., Khazaeli, M.B., Rosenfeld, M.E., Gillespie, G.Y., Grizzle, W.E., Liu, T., and Curiel, D.T., 1996. Enhancement of radiolabeled antibody binding and tumor localization through adenoviral transduction of the human carcinoembryonic antigen gene. Gene Ther.3:567–580.
Robertson, D., 1998. Genetech’s anticancer Mab expected by November. Nature Biotechnology16:615.
Rodriguez, R., Schuur, E.R., Lim, H.Y., Henderson, G.A., Simons, J.W., and Henderson, D.R., 1997. Prostate attentuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Research57:2559–2563.
Rosenberg, S.A., 1998. New opportunities for the development of cancer immunotherapies. Cancer J. Sci. Am. 4 Suppl. 1:S1–4.
Roy, S., Shirley, P.S., McClelland, A., and Kaleko, M., 1998. Circumvention of immunity to the adenovirus major coat protein hexon. J. Virol.72:6875–6879.
Smith T.A., White, B.D., Gardner, J.M., Kaleko, M., and McClelland, A., 1996. Transient immunosuppression permits successful repetitive intravenous administration of an adenvirus vector. Gene Ther.3:496–502.
Somia, N.V., Zoppe, M., and Verma, I.M., 1995. Generation of targeted retroviral vectors by using single-chain variable fragment: An approach to in vivo gene delivery. Proc. Natl. Acad. Sci. USA.92:7570–7574.
Smith, T.A.G., Mehaffey, M.G., Kayda, D.B., Saunders, J.M., Yei, S., Trapnell, B.C., McClelland, A., and Kaleko, M., 1993. Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice. Nat. Genet.5:397–402.
Sosnowski B.A., Gonzalez A.M., Chandler L.A., Buechler Y.J., Pierce G.F., and Baird A., 1996. Targeting DNA to cells with basic fibroblast growth factor (FGF2). J. Biol. Chem.271:33647–33653.
Sterman D.H., Kaiser, L.R., and Albelda, S.M., 1998. Gene therapy for malignant pleural mesothelioma. Hematol. Oncol. Clin. North. Am.12:553–568.
Stevenson, S.C., Rollence, M.L., White, B., Weaver, L., and McClelland, A., 1995. Human adenovirus serotypes 3 and 5 bind to two different cellular receptor via the fiber head domain, J. Virology69:2850–2857.
Stevenson, S.C., Rollence, M.L., Marshall-Neff, J., and McClelland, A., 1997. Selective targeting of human cells by a chimeric adenovirus vector containing a modified fiber protein, J. Virology71:4782–4790.
Tomki R.P., Xu R., and Philipson L., 1997. HCAR and MCAR: The human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc. Natl. Acad Sci. U.S.A., 94:3352–3356.
Von Seggern, D., Kehler J., Endo R.I., and Nemerow G.R., 1998. Complementation of a fibre mutant adenovirus by packaging cell lines stably expressing the adenovirus type 5 fibre protein, J. General Virology.79:1461–1468.
Wickham, T.J., Mathias, P., Cheresh, D.A., and Nemerow, G.R., 1993. Integrins avb3 and avb5 promote adenovirus internalization but not virus attachment. Cell.73:309–319.
Wickham, T.J., Carrion, M.E., and Kovesdi, I., 1995. Targeting of adenovirus penton base to new receptors though replacement of its RGD motif with other receptor-specific motifs. Gene Therapy2:750–756.
Wickham, T.J., Roelvink, P.W., Brough, D.E., and Kovesdi, I., 1996. Adenovirus targeted to heparin-containing receptors increase its gene delivery efficiency to multiple cell types. Nature Biotechnol.14:1570–1573.
Wickham, T.J., Segal, D.M., Roelvink, P.W., Carrion, M.E., Lizonova, A., Lee, G.M., and Kovesdi, I., 1996. Targeted adenovirus gene transfer to endothelial and smooth muscle cells by bispecific antibodies. J. Virology.70:6831–6838.
Woodle, M.C., and Storm, G. eds., 1998. Long circulating liposomes, old drugs, new therapeutics. Spinger-Verlag Berlin-Heidelberg and Landes Bioscience, Georgetown, Texas.
Yang, J., 1999. Direct intratumoral injection of naked DNA, in Gene Therapy of cancer: methods and protocols, (W. Walther and U. Stein, eds.), in press.
Yazaki, T., Manz, H.J., Rabkin, S.D., and Martuza, R.L., Treatment of human malignant meningiomas by G207, a replication-competent mulitmutated herpes simplex virus 1. Cancer Res.55:4752–4756.
Xia D., Henry L.J., Gerard R.D., and Deisenhofer J., 1994. Crystal structure of the receptor binding domain of adenovirus type 5 fiber protein at 1.7 A resolution. Structure.2:1259–1270.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Kluwer Academic Publishers
About this chapter
Cite this chapter
Hallenbeck, P.L., Stevenson, S.C. (2002). Targetable Gene Delivery Vectors. In: Habib, N.A. (eds) Cancer Gene Therapy. Advances in Experimental Medicine and Biology, vol 465. Springer, New York, NY. https://doi.org/10.1007/0-306-46817-4_4
Download citation
DOI: https://doi.org/10.1007/0-306-46817-4_4
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-306-46191-0
Online ISBN: 978-0-306-46817-9
eBook Packages: Springer Book Archive